Copyright
        ©The Author(s) 2025.
    
    
        World J Gastroenterol. Jan 7, 2025; 31(1): 98561
Published online Jan 7, 2025. doi: 10.3748/wjg.v31.i1.98561
Published online Jan 7, 2025. doi: 10.3748/wjg.v31.i1.98561
            Table 1 Primary antibodies used in this study
        
    | Antibody name | Host | Brand, category No. | Country | Applications and dilution | ||
| Western blot | IHC | IF | ||||
| ACTA2 | Rabbit | Proteintech | China | 1:5000 | 1:800 | 1:100 | 
| FN | Rabbit | Proteintech | China | 1:1000 | 1:200 | 1:100 | 
| Collagen Ⅰ | Rabbit | Proteintech | China | 1:1000 | 1:500 | 1:100 | 
| TGF-β1 | Mouse | Novus | United States | 1:1000 | - | - | 
| Smad2 | Rabbit | CST | United States | 1:1000 | - | - | 
| Smad3 | Rabbit | CST | United States | 1:1000 | - | - | 
| P-Smad2 | Rabbit | Affinity Biotech | United States | 1:1000 | 1:100 | 1:50 | 
| P-Smad3 | Rabbit | Affinity Biotech | United States | 1:1000 | 1:100 | 1:50 | 
| Vimentin | Rabbit | Proteintech | China | - | - | 1:200 | 
| Cytokerin | Rabbit | Abcam | China | - | - | 1:200 | 
| GAPDH | Rabbit | CST | United States | 1:1000 | - | - | 
            Table 2 Primers used in this study
        
    | Primer name | Forward 5’ to 3’ | Reverse 5’ to 3’ | 
| ACTA2 | TAGAACACGGCATCATCACCAACTG | TGGGGCAACACGAAGCTCATTG | 
| FN | GTGTGGATGTCCTGCCTGTCAAC | GCTTGCTTTCCCTGCCCTGATG | 
| Collagen I | CTCAAGATGTGCCACTCCGACTG | GTCTCGCCTGTCTCCATGTTGC | 
| TGF-β1 | GACCGCAACAACGCAATCTATGAC | GGCACTGCTTCCCGAATGTCTG | 
| Smad2 | ATGTCGTCCATCTTGCCATTCACTC | TGCTTTCTCACACCACTTCTCTTCC | 
| Smad3 | TGTCGTCCATCCTGCCCTTCAC | ACTTCTCCTCCTGCCCGTTCTG | 
| GAPDH | ATGATTCCACCCACGGCAAGTTC | AGCACCAGCATCACCCCATTTG | 
            Table 3 Summary of statistical results for the Control, Kangfuxin solution-treated, and PDNN-treated groups
        
    | Control | KFX | PDNN | P value | |
| Weight loss, kg | 4.08 ± 0.69 | 1.98 ± 0.79b | 2.03 ± 1.07b | 0.011 | 
| Dysphagia score | 3.50 ± 0.58 | 1.75 ± 0.50b | 1.25 ± 0.96a | 0.004 | 
| Esophageal stricture rate | 87.68 ± 1.90 | 59.67 ± 5.05a | 53.90 ± 6.29a | < 0.001 | 
| Number of inflammatory cells | 1976.25 ± 116.39 | 950.25 ± 276.92a,e | 1651.50 ± 153.97c | < 0.001 | 
| Number of fibroblasts | 5736.25 ± 691.56 | 1537.00 ± 118.89a, f | 710.00 ± 347.14a | < 0.001 | 
| Fibrosis area ratio | 66.20 ± 8.95 | 34.63 ± 3.64a,f | 23.47 ± 2.65a | < 0.001 | 
| Thickness of submucosal fibrosis, um | 853.93 ± 20.16 | 672.20 ± 28.69a,d | 512.83 ± 42.73a | < 0.001 | 
- Citation: Zhou X, Ma D, He YX, Jin J, Wang HL, Wang YF, Yang F, Liu JQ, Chen J, Li Z. Kangfuxin solution alleviates esophageal stenosis after endoscopic submucosal dissection: A natural ingredient strategy. World J Gastroenterol 2025; 31(1): 98561
 - URL: https://www.wjgnet.com/1007-9327/full/v31/i1/98561.htm
 - DOI: https://dx.doi.org/10.3748/wjg.v31.i1.98561
 
